Chimeric antigen receptor modified T-cells for cancer treatment
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory/relapsed acute lymphoblastic leukemia (ALL), an...
Saved in:
Main Authors: | , , |
---|---|
Format: | article |
Language: | EN |
Published: |
KeAi Communications Co., Ltd.
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/5f052065f6bb40cbb3a2e894eb1bf860 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!